{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:39:31Z","timestamp":1790271571141,"version":"4.1.0"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>This Policy Statement was retired January 2009.<\/jats:title>\n               <jats:p>Two peaks in the incidence of invasive meningococcal disease (IMD) occur in pediatric patients: infants younger than 1 year and adolescents 15 to 18 years of age. Although the incidence of IMD is highest in infants, the case-fatality rate is highest in adolescents (\u223c20%). Epidemiologic studies also have demonstrated increased risk of IMD among college freshman living in dormitories compared with other college students and similarly aged persons in the general population. At least 75% of cases of IMD in 11- to 18-year-olds are caused by serogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immunization with quadrivalent meningococcal vaccines. Meningococcal A, C, Y, W-135 conjugate vaccine (MCV4) was licensed in 2005 for use in people 11 to 55 years of age. On the basis of data indicating increased risk of meningococcal disease and fatality among certain adolescents and college students, the American Academy of Pediatrics recommends administration of MCV4 to young adolescents (at the 11- to 12-year visit), students entering high school or 15-year-olds, and college freshmen who will be living in dormitories. For pediatric patients 11 years and older who are at increased risk of meningococcal disease, MCV4 also is recommended. The purposes of this statement are to provide the rationale for routine use of MCV4 in adolescents and to update recommendations for use of the meningococcal polysaccharide vaccine in pediatric patients.<\/jats:p>","DOI":"10.1542\/peds.2005-1314","type":"journal-article","created":{"date-parts":[[2005,7,2]],"date-time":"2005-07-02T00:59:51Z","timestamp":1120265991000},"page":"496-505","source":"Crossref","is-referenced-by-count":68,"title":["Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients"],"prefix":"10.1542","volume":"116","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,8,1]]},"reference":[{"key":"2023081714260619400_R1","unstructured":"Centers for Disease Prevention and Control. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082000;49(RR-7):1\u201310"},{"key":"2023081714260619400_R2","unstructured":"Bilukha OO, Rosenstein N; Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR.\u20082005;54(RR-7):1\u201321"},{"key":"2023081714260619400_R3","doi-asserted-by":"crossref","unstructured":"Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA.\u20082001;286:694\u2013699","DOI":"10.1001\/jama.286.6.694"},{"key":"2023081714260619400_R4","unstructured":"American Academy of Pediatrics. Meningococcal infections. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infections Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics. 2003;430\u2013436"},{"key":"2023081714260619400_R5","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students). Pediatrics.\u20082000;106:1500\u20131504","DOI":"10.1542\/peds.106.6.1500"},{"key":"2023081714260619400_R6","doi-asserted-by":"crossref","unstructured":"Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA.\u20081995;273:383\u2013389","DOI":"10.1001\/jama.273.5.383"},{"key":"2023081714260619400_R7","unstructured":"Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989\u20131991. MMWR CDC Surveill Summ.\u20081993;42(2):21\u201330"},{"key":"2023081714260619400_R8","doi-asserted-by":"crossref","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992\u20131996. J Infect Dis.\u20081999;180:1894\u20131901","DOI":"10.1086\/315158"},{"key":"2023081714260619400_R9","doi-asserted-by":"crossref","unstructured":"Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA.\u20082001;286:688\u2013693","DOI":"10.1001\/jama.286.6.688"},{"key":"2023081714260619400_R10","doi-asserted-by":"crossref","unstructured":"Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA.\u20081999;281:1906\u20131910","DOI":"10.1001\/jama.281.20.1906"},{"key":"2023081714260619400_R11","doi-asserted-by":"crossref","unstructured":"Froeschle J. Meningococcal disease in college students. Clin Infect Dis.\u20081999;29:215\u2013216","DOI":"10.1086\/520166"},{"key":"2023081714260619400_R12","unstructured":"Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081997;46(RR-5):1\u201351"},{"key":"2023081714260619400_R13","unstructured":"Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep.\u20082002;51(RR-2):1\u201335"},{"key":"2023081714260619400_R14","doi-asserted-by":"crossref","unstructured":"Borrow R, Southern J, Andrews N, et al. Comparison of antibody kinetics following meningococcal serogroup C conjugate vaccine between healthy adults previously vaccinated with meningococcal A\/C polysaccharide vaccine and vaccine-naive controls. Vaccine.\u20082001;19:3043\u20133050","DOI":"10.1016\/S0264-410X(01)00050-0"},{"key":"2023081714260619400_R15","doi-asserted-by":"crossref","unstructured":"Artenstein MS, Gold R, Zimmerly JG, Wyle FA, Schneider H, Harkins C. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med.\u20081970;282:417\u2013420","DOI":"10.1056\/NEJM197002192820803"},{"key":"2023081714260619400_R16","doi-asserted-by":"crossref","unstructured":"Rosenstein N, Levine O, Taylor J, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA.\u20081998;279:435\u2013439","DOI":"10.1001\/jama.279.6.435"},{"key":"2023081714260619400_R17","doi-asserted-by":"crossref","unstructured":"Cochi SL, Markowitz L, Joshi DD, et al. Control of epidemic group A meningococcal meningitis in Nepal. Int J Epidemiol.\u20081987;16:91\u201397","DOI":"10.1093\/ije\/16.1.91"},{"key":"2023081714260619400_R18","doi-asserted-by":"crossref","unstructured":"MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugates vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA.\u20081998;280:1685\u20131689","DOI":"10.1001\/jama.280.19.1685"},{"key":"2023081714260619400_R19","doi-asserted-by":"crossref","unstructured":"Lepow ML, Goldschneider I, Gold R, Randolph M, Gotschlich EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics.\u20081977;60:673\u2013680","DOI":"10.1542\/peds.60.5.673"},{"key":"2023081714260619400_R20","doi-asserted-by":"crossref","unstructured":"Reingold AL, Broome CV, Hightower AW, et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet.\u20081995;2(8447):114\u2013118","DOI":"10.1016\/S0140-6736(85)90224-7"},{"key":"2023081714260619400_R21","unstructured":"Yergeau A, Alain L, Pless R, Robert Y. Adverse events temporally associated with meningococcal vaccines. CMAJ.\u20081996;154:503\u2013507"},{"key":"2023081714260619400_R22","doi-asserted-by":"crossref","unstructured":"Roberts J, Bryett K. Incidence of reactions to meningococcal A and C vaccine among U.K. schoolchildren. Public Health.\u20081988;102:471\u2013476","DOI":"10.1016\/S0033-3506(88)80085-4"},{"key":"2023081714260619400_R23","doi-asserted-by":"crossref","unstructured":"Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis.\u20081992;165(suppl):S49\u2013S52","DOI":"10.1093\/infdis\/165-Supplement_1-S49"},{"key":"2023081714260619400_R24","doi-asserted-by":"crossref","unstructured":"Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect.\u20081988;16:55\u201359","DOI":"10.1016\/S0163-4453(88)96117-8"},{"key":"2023081714260619400_R25","unstructured":"Frasch CE. Regulatory perspectives in vaccine licensure. In: Ellis RW, Granoff DM, eds. Development and Clinical Uses of Haemophilus influenzae Type b Conjugate Vaccines. New York, NY: Marcel Dekker; 1994:435\u2013453"},{"key":"2023081714260619400_R26","doi-asserted-by":"crossref","unstructured":"Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health.\u20082001;37:S34\u2013S36","DOI":"10.1046\/j.1440-1754.2001.00738.x"},{"key":"2023081714260619400_R27","doi-asserted-by":"crossref","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski E, Miller EB. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ.\u20082003;326:365\u2013366","DOI":"10.1136\/bmj.326.7385.365"},{"key":"2023081714260619400_R28","doi-asserted-by":"crossref","unstructured":"Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet.\u20082004;364:365\u2013367","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"2023081714260619400_R29","doi-asserted-by":"crossref","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J Exp Med.\u20081969;129:1307\u20131326","DOI":"10.1084\/jem.129.6.1307"},{"key":"2023081714260619400_R30","doi-asserted-by":"crossref","unstructured":"Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine.\u20082001;20(suppl 1):S58\u2013S67","DOI":"10.1016\/S0264-410X(01)00299-7"},{"key":"2023081714260619400_R31","doi-asserted-by":"crossref","unstructured":"Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol.\u20082003;10:780\u2013786","DOI":"10.1128\/CDLI.10.5.780-786.2003"},{"key":"2023081714260619400_R32","doi-asserted-by":"crossref","unstructured":"Jodar L, Griffiths E, Feavers I. Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines. Vaccine.\u20082004;22:1047\u20131053","DOI":"10.1016\/j.vaccine.2003.08.040"},{"key":"2023081714260619400_R33","doi-asserted-by":"crossref","unstructured":"Sippel JE. Meningococci.Crit Rev Microbiol.\u20081981;8:267\u2013302","DOI":"10.3109\/10408418109085081"},{"key":"2023081714260619400_R34","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Product approval information\u2014licensing action. 2005. Available at: www.fda.gov\/cber\/products\/mpdtave011405.htm. Accessed May 16, 2005"},{"key":"2023081714260619400_R35","doi-asserted-by":"crossref","unstructured":"Shephard CW, Ortega-Sanchez IR, Scott RD II, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics.\u20082005;115:1220\u20131232","DOI":"10.1542\/peds.2004-2514"},{"key":"2023081714260619400_R36","doi-asserted-by":"crossref","unstructured":"Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet.\u20081991;338:1093\u20131096","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"2023081714260619400_R37","doi-asserted-by":"crossref","unstructured":"Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Microbiol.\u20082000;38:3323\u20133328","DOI":"10.1128\/JCM.38.9.3323-3328.2000"},{"key":"2023081714260619400_R38","unstructured":"US Preventive Services Task Force. Appendix A: task force ratings. In: Guide to Clinical Preventive Services. 2nd ed. Alexandria, VA: International Medical Publishing; 1996:861\u2013865"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/2\/496\/1519705\/zpe00805000496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/2\/496\/1519705\/zpe00805000496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T14:27:05Z","timestamp":1692282425000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/2\/496\/62934\/Prevention-and-Control-of-Meningococcal-Disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,8,1]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-1314","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}